DGM
MGNX icon

Darwin Global Management’s MacroGenics MGNX Stock Holding History

Darwin Global Management’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-286,195
Closed -$9.12M – 17
2021
Q1 		$9.12M Buy
+286,195
New +$6.95M 1.78% 6

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Darwin Global Management's MGNX Position: Q2 2021 in Review

Darwin Global Management sold out of MacroGenics (MGNX) in Q2 2021, closing a stake of 286,195 shares — an estimated $9.12M sold.

Darwin Global Management first reported a position in MGNX in Q1 2021 and held it in 1 quarter. The position peaked at $9.12M in Q1 2021. 149 funds tracked by Wall St. Rank hold MGNX as of Q2 2021.

  • Darwin Global Management reported no remaining MacroGenics position as of Q2 2021 after selling out during the quarter.
  • Darwin Global Management sold 286,195 MacroGenics shares in Q2 2021, an estimated $9.12M.
  • Darwin Global Management first reported a position in MacroGenics in Q1 2021 and held it in 1 quarter.
  • Darwin Global Management's MacroGenics position peaked at $9.12M in Q1 2021.
  • 149 funds tracked by Wall St. Rank held MacroGenics as of Q2 2021.

Based on Darwin Global Management's 13F filing for Q2 2021, filed 16 Aug 2021.